Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Stock Short Interest Report for October

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) was the target of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 1,324 shares, an increase of 586.0% from the October 15th total of 193 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 8,514 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. DLD Asset Management LP boosted its position in Oaktree Acquisition Corp. III Life Sciences by 0.9% during the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after acquiring an additional 1,200 shares during the period. Rangeley Capital LLC increased its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 52.8% during the first quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after purchasing an additional 21,156 shares during the period. Finally, Periscope Capital Inc. acquired a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the third quarter valued at $3,488,000.

Oaktree Acquisition Corp. III Life Sciences Trading Up 0.1%

Oaktree Acquisition Corp. III Life Sciences stock traded up $0.01 during midday trading on Thursday, reaching $10.71. 825 shares of the stock traded hands, compared to its average volume of 5,153. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $10.50 and a fifty-two week high of $10.93. The firm has a fifty day moving average price of $10.74 and a two-hundred day moving average price of $10.70.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.07 EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Oaktree Acquisition Corp. III Life Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Hold rating. According to MarketBeat, the stock currently has an average rating of “Hold”.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) formed to pursue a business combination with a company in the life sciences sector. Its potential transactions could include a merger, acquisition, or similar combination. The company was sponsored by Oaktree Capital Management. As a SPAC, it did not have its own operating business or sell products and services; its intended role was to identify and combine with a business in its target sector.